Technical Analysis for INBX - Inhibrx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 1.37% | |
| Stochastic Buy Signal | Bullish | 1.37% | |
| Pocket Pivot | Bullish Swing Setup | 1.37% | |
| Oversold Stochastic | Weakness | 1.37% | |
| Lower Bollinger Band Walk | Weakness | 1.89% | |
| Outside Day | Range Expansion | 1.89% | |
| Gapped Up | Strength | 1.89% | |
| Lower Bollinger Band Touch | Weakness | 1.89% | |
| Oversold Stochastic | Weakness | 1.89% | |
| Stochastic Reached Oversold | Weakness | 7.73% |
| Alert | Time |
|---|---|
| Up 2% | about 1 hour ago |
| Up 1% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 1 hour ago |
| Down 2 % | about 3 hours ago |
| Down 1% | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/26/2025
Inhibrx, Inc. Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a multivalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarcomas; and INBRX-105, an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with PD-L1 expressing tumors. The company's therapeutic candidates also comprise INBRX-101, an Fc-fusion protein-based therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with alpha-1 antitrypsin deficiency; and INBRX-103, a mAb in Phase 1 clinical trials that targets cluster of differentiation 47. Its preclinical programs include INBRX-106, a sdAb-based hexavalent agonist of OX40 for a range of oncology indications; and INBRX-111, a multi-functional antibody that targets Pseudomonas aeruginosa. The company was founded in 2010 and is headquartered in La Jolla, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Solid Tumors Tumor Clinical Research Clinical Trial Sarcoma Antitrypsin Deficiency Fusion Protein Pseudomonas Clusters Of Differentiation Pseudomonas Aeruginosa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 18.95 |
| 52 Week Low | 10.8 |
| Average Volume | 80,517 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 14.89 |
| 20-Day Moving Average | 14.63 |
| 10-Day Moving Average | 14.60 |
| Average True Range | 1.00 |
| RSI (14) | 40.48 |
| ADX | 16.81 |
| +DI | 20.57 |
| -DI | 21.89 |
| Chandelier Exit (Long, 3 ATRs) | 13.82 |
| Chandelier Exit (Short, 3 ATRs) | 15.52 |
| Upper Bollinger Bands | 16.44 |
| Lower Bollinger Band | 12.82 |
| Percent B (%b) | 0.2 |
| BandWidth | 24.78 |
| MACD Line | -0.34 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.2182 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.15 | ||||
| Resistance 3 (R3) | 16.30 | 15.58 | 15.72 | ||
| Resistance 2 (R2) | 15.58 | 14.92 | 15.51 | 15.57 | |
| Resistance 1 (R1) | 14.56 | 14.50 | 14.20 | 14.41 | 15.42 |
| Pivot Point | 13.84 | 13.84 | 13.66 | 13.77 | 13.84 |
| Support 1 (S1) | 12.82 | 13.18 | 12.46 | 12.67 | 11.66 |
| Support 2 (S2) | 12.10 | 12.76 | 12.03 | 11.51 | |
| Support 3 (S3) | 11.08 | 12.10 | 11.37 | ||
| Support 4 (S4) | 10.93 |
